Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design

Ryan Cross

Senior Science Correspondent

Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed drug discovery collaborations with AstraZeneca, Bristol …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: Har­vard start­up rais­es $26M, strikes three phar­ma part­ner­ships for AI an­ti­body de­sign

Senior Science Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: Harvard startup raises $26M, strikes three pharma partnerships for AI antibody design